ECMO benefit ‘unclear’ in COVID-19 critically ill

More data on outcomes for patients given the therapy is urgently needed, researchers say

Extracorporeal membrane oxygenation (ECMO) may not reduce mortality in critically ill patients with COVID-19, new findings suggest.

US and Italian researchers analysed four studies including a total of 562 patients with COVID-19, 42% of whom developed acute respiratory distress syndrome (ARDS).

Some 17 of the patients with ARDS received ECMO, and their mortality rate was 94%, compared with 71% for the patients with ARDS given conventional therapy — however, the difference in mortality risk was not statistically significant.

Mortality was 65% in the largest study of patients with MERS who received ECMO, the authors note.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .